uniQure Past Earnings Performance
Past criteria checks 0/6
uniQure has been growing earnings at an average annual rate of 32.3%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 64.8% per year.
Key information
32.3%
Earnings growth rate
35.7%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 64.8% |
Return on equity | -29.8% |
Net Margin | -204.1% |
Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How uniQure makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 22 | 61 | -125 | 51 | 51 |
30 Jun 22 | 62 | -114 | 49 | 0 |
31 Mar 22 | 525 | 324 | 55 | 0 |
31 Dec 21 | 524 | 330 | 56 | 0 |
30 Sep 21 | 500 | 321 | 54 | 0 |
30 Jun 21 | 500 | 303 | 52 | 0 |
31 Mar 21 | 38 | -139 | 46 | 0 |
31 Dec 20 | 38 | -125 | 43 | 0 |
30 Sep 20 | 6 | -166 | 40 | 0 |
30 Jun 20 | 5 | -136 | 38 | 0 |
31 Mar 20 | 6 | -124 | 35 | 0 |
31 Dec 19 | 7 | -124 | 34 | 0 |
30 Sep 19 | 6 | -105 | 32 | 0 |
30 Jun 19 | 8 | -103 | 29 | 0 |
31 Mar 19 | 9 | -92 | 27 | 0 |
31 Dec 18 | 11 | -83 | 25 | 0 |
30 Sep 18 | 12 | -90 | 26 | 0 |
30 Jun 18 | 11 | -78 | 25 | 0 |
31 Mar 18 | 13 | -78 | 25 | 0 |
31 Dec 17 | 13 | -79 | 25 | 0 |
30 Sep 17 | 20 | -67 | 24 | 0 |
30 Jun 17 | 25 | -72 | 23 | 0 |
31 Mar 17 | 24 | -71 | 26 | 0 |
31 Dec 16 | 25 | -73 | 25 | 0 |
30 Sep 16 | 20 | -76 | 28 | 0 |
30 Jun 16 | 16 | -90 | 29 | 0 |
31 Mar 16 | 14 | -90 | 26 | 0 |
31 Dec 15 | 11 | -82 | 23 | 0 |
Quality Earnings: UQ1 is currently unprofitable.
Growing Profit Margin: UQ1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: UQ1 is unprofitable, but has reduced losses over the past 5 years at a rate of 32.3% per year.
Accelerating Growth: Unable to compare UQ1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UQ1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: UQ1 has a negative Return on Equity (-29.77%), as it is currently unprofitable.